Physician profile
Meaghan M Ryan
NPI 1407295652
$3,749.62
in general payments reported to CMS, 2019-2025
12 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $578 · 2022: $167 · 2023: $733 · 2024: $768 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807 · Travel and Lodging: $942 · Education: $165 · Consulting Fee: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.29 |
| Travel and Lodging | $942.48 |
| Education | $164.98 |
| Consulting Fee | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,183.86 | 2025 | Trek |
| Abbvie INC. | $715.44 | 2023-2025 | |
| Incyte Corporation | $458.34 | 2021-2025 | Niktimvo |
| Adaptive Biotechnologies Corporation | $285.24 | 2021-2023 | Clonoseq |
| Janssen Biotech, INC. | $209.50 | 2023-2024 | Talvey, Imbruvica, Tecvayli |
| Janssen Scientific Affairs, LLC | $204.41 | 2021-2024 | Talvey |
| Celgene Corporation | $196.15 | 2022-2025 | Abecma, Breyanzi, Pomalyst |
| Sobi, INC | $157.54 | 2024 | |
| Legend Biotech USA INC. | $124.95 | 2025 | Carvykti |
| Sanofi-Aventis U.S. LLC | $123.17 | 2022 | |
| Kite Pharma, INC. | $66.53 | 2024 | |
| Genmab U.S., INC. | $24.49 | 2023 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.